Abstract
Monoclonal antibodies were developed against human pancreatic prophospholipase A2 (proPLA2). They had high affinity for proPLA2 and small cross reactivities with human pancreatic phospholipase A2 (PLA2). By S-Sepharose ion-exchange chromatography combined with radioimmunoassay for proPLA2 and that for PLA2 both using monoclonal antibodies, proPLA2 and PLA2 in human sera could be separated and measured. In healthy individuals, proPLA2 proved to be the major form of the enzyme, while two out of three patients with pancreatitis showed a larger proportion of PLA2, which may be an indication of the severity of the pancreatitis. In patients with pancreatic cancer and chronic renal failure, proPLA2 remained in larger proportion in spite of the very high radioimmunoassay level of PLA2. The concentrations of both proPLA2 and PLA2 in human sera could be estimated by a combination of the two radioimmunoassay systems, suggesting that this combination radioimmunoassay could be used to more precisely diagnose pancreatitis and other diseases exhibiting high levels of immunoreactive PLA2 than a single radioimmunoassay system.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
